Literature DB >> 27723543

Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study.

Adrian L Lopresti1, Peter D Drummond2.   

Abstract

BACKGROUND: Several studies have supported the antidepressant effects of curcumin (from the spice turmeric) and saffron for people with major depressive disorder. However, these studies have been hampered by poor designs, small sample sizes, short treatment duration, and similar intervention dosages. Furthermore, the antidepressant effects of combined curcumin and saffron administration are unknown.
METHODS: In a randomised, double-blind, placebo-controlled study, 123 individuals with major depressive disorder were allocated to one of four treatment conditions, comprising placebo, low-dose curcumin extract (250mg b.i.d.), high-dose curcumin extract (500mg b.i.d.), or combined low-dose curcumin extract plus saffron (15mg b.i.d.) for 12 weeks. The outcome measures were the Inventory of Depressive Symptomatology self-rated version (IDS-SR30) and Spielberger State-Trait Anxiety Inventory (STAI).
RESULTS: The active drug treatments (combined) were associated with significantly greater improvements in depressive symptoms compared to placebo (p=.031), and superior improvements in STAI-state (p<.001) and STAI-trait scores (p=.001). Active drug treatments also had greater efficacy in people with atypical depression compared to the remainder of patients (response rates of 65% versus 35% respectively, p=.012). No differences were found between the differing doses of curcumin or the curcumin/saffron combination. LIMITATIONS: Investigations with larger sample sizes are required to examine the efficacy of differing doses of curcumin and saffron/curcumin combination. Its effects in people with atypical depression also require examination in larger scale studies.
CONCLUSIONS: Active drug treatments comprising differing doses of curcumin and combined curcumin/saffron were effective in reducing depressive and anxiolytic symptoms in people with major depressive disorder. Crown
Copyright © 2016. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidepressant; Clinical Trial; Curcumin; Depression; Saffron; Turmeric

Mesh:

Substances:

Year:  2016        PMID: 27723543     DOI: 10.1016/j.jad.2016.09.047

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  22 in total

Review 1.  [Herbal medicines for psychiatric disorders].

Authors:  D Anheyer; H Haller; P Klose; H Cramer; G Dobos
Journal:  Nervenarzt       Date:  2018-09       Impact factor: 1.214

Review 2.  Protective Effects of Curcumin Against Ischemia-Reperfusion Injury in the Nervous System.

Authors:  Kowsar Bavarsad; George E Barreto; Mousa-Al-Reza Hadjzadeh; Amirhossein Sahebkar
Journal:  Mol Neurobiol       Date:  2018-06-09       Impact factor: 5.590

3.  Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.

Authors:  Buranee Kanchanatawan; Sookjaroen Tangwongchai; Atapol Sughondhabhirom; Siriluck Suppapitiporn; Solaphat Hemrunrojn; André F Carvalho; Michael Maes
Journal:  Neurotox Res       Date:  2018-01-11       Impact factor: 3.911

Review 4.  Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-03-14       Impact factor: 3.575

5.  A diet enriched with curcumin promotes resilience to chronic social defeat stress.

Authors:  Antonio V Aubry; Hameda Khandaker; Rebecca Ravenelle; Itamar S Grunfeld; Valentina Bonnefil; Kenny L Chan; Flurin Cathomas; Jia Liu; Glenn E Schafe; Nesha S Burghardt
Journal:  Neuropsychopharmacology       Date:  2018-12-12       Impact factor: 7.853

Review 6.  Current Research on Complementary and Alternative Medicine (CAM) in the Treatment of Major Depressive Disorder: An Evidence-Based Review.

Authors:  Vladimir Trkulja; Hrvoje Barić
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets.

Authors:  David S Baldwin; Ruihua Hou; Robert Gordon; Nathan T M Huneke; Matthew Garner
Journal:  CNS Drugs       Date:  2017-04       Impact factor: 5.749

Review 8.  Mechanism and therapeutic strategies of depression after myocardial infarction.

Authors:  Ying Yang; Xuping Li; Sixuan Chen; Mingzhu Xiao; Zhongqiu Liu; Jingyan Li; Yuanyuan Cheng
Journal:  Psychopharmacology (Berl)       Date:  2021-02-16       Impact factor: 4.530

Review 9.  Effects of Curcumin on Depression and Anxiety: A Narrative Review of the Recent Clinical Data.

Authors:  Mohammad Amin Khodadadegan; Shakiba Azami; Paul C Guest; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  New Somatic Treatments for Child and Adolescent Depression.

Authors:  Kathryn R Cullen; Laura E Padilla; Victoria N Papke; Bonnie Klimes-Dougan
Journal:  Curr Treat Options Psychiatry       Date:  2019-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.